康复新液湿敷联合内瘘图谱在肝素涂层人工血管早期使用中的效果观察

杨 晗 廖 丹*
绵阳市中心医院 四川 绵阳 621000

【摘 要】：目的： AVG AVG
方法：
39 ePTFE 28
Propaten 11
结果： 100%
P 0.05
P 0.05 结论：
AVG
AVG
AVG

【关键词】：

Effect of Kangfuxin Liquid Wet Compress Combined with Internal Fistula Map in Early Application of Heparin-coated Artificial Blood Vessel

Han Yang Dan Liao*

Mianyang Central Hospital Sichuan Mianyang 621000

Abstract: Objective: To investigate the effect of Kangfuxin liquid wet application on reducing the early limb swelling of heparin-coated artificial blood vessel (AVG) internal fistula side, preventing wound infection, promoting the early use of AVG, and improving the success rate of puncture and reducing the complications of internal fistula. Methods: A total of 39 patients with end-stage renal disease who underwent pedestrian hematopoietic fistula surgery in our hospital were selected, 28 patients with extended expanded polytetrafluoroethylene (ePTFE) artificial blood vessel type were divided into the control group, and 11 patients with heparin-coated artificial blood vessel (Propaten) were divided into the experimental group. The control group received routine nursing of artificial blood vessel internal fistula after operation. On the basis of the control group, the experimental group used Kangfuxin liquid wet compress the swollen parts and wounds of the limbs on the side of the operation, and the artificial vascular fistula map was used for puncture. Results: The success rate of operation in the two groups was 100%. The experimental group was significantly better than the control group in reducing limb swelling, shortening limb swelling time, and preventing wound infection, and the difference was statistically significant ($P < 0.05$). The success rate of one puncture and the incidence of fistula complications in the experimental group were significantly better than those in the control group ($P < 0.05$). Conclusion: The application of Kangfuxin liquid to wet compress the swollen parts and wounds of limbs after heparin-coated artificial vascular surgery can effectively reduce the swelling of limbs, shorten the swelling time of limbs, and prevent wound infection. Combined with the puncture atlas of artificial vascular internal fistula, the complications of AVG internal fistula are effectively avoided, the service life of AVG is prolonged, and the lifeline of dialysis patients is protected. This method is worthy of promotion in clinical practice.

Keywords: Rehabilitation of new fluid; Internal fistula map; Heparin coating; Early use of artificial blood vessels

[1]

3

“U”

GORE

arteriovenousvascular graft AVG ePTFE

AVG AVF Propaten

2 3

[2] 2.2

2.2.1

AVG 1

AVG AVG 2

Propaten

AVG 3

24h

[3] AVF 4 3-5 14 5

6 6-8

7

“U” AVG

AVG 95 [4] 2.2.2

AVG AVG

2017 1 3

10 9 12

10-18

2017 10 AVG

1 研究对象与方法

1.1

2017 10 2020 3

39 2

ePTFE 28

Propaten 11 U

31 8 5mm 5mm

55 89 58.2 ± 4.25

16 23 2 19

21 12 4

2 2-3 4h 4

3-5%

“U”

≥ 2.5mm ≥ 1

3mm

3

2 研究方法

[5] 3

2.1 B

“U” “U”

5cm

1cm A_1-A_6

V_1-V_6 6

1 4

“ ” 10 2.3

6 17G 2.3.1

1

3 U

5mm 5mm

A1 V1 A6 V6

3 7 14 2

8cm

3 200-220ml/min 5mm

15-20 [6]

2.3.2

5

4

1 XX

_____ □ □ ___ _____ cm _____kg BMI _____ Propaten□ ePTFE□																									
										mmhg				ml/min										
									mm		17G	16G	A	V	1										
12/3	√			√				√	260		√		A1	V1	√		120	220							
□ □																									
“ √ ”																									

2.3.3

P 0.05

1 2

1

2.4 P 0.05 3 3

spss25.0

± $\bar{x} \pm s$ t p 0.05 4 P 0.05

8 1

3 结果

100%

3 3

2 3 7 14

			3			7			14	
	28	1	7	20	7	6	15	9	6	13
	11	3	4	4	7	3	1	10	1	0
z			-2.26			-2.64			-3.30	
p			0.02			0.01			0.00	

3 3

					p P 0.05
	28	1340	1270 94.8%	21	
	11	726	722 99 4%	5	0.00

* P 0.05

4 %

	28	1 3.5	12 42.8	11 39.2	15 53.5	4 14.3
	11	0 0	1 9	0 0	2 18.2	1 9
t		0.40	4.05	6.02	4.02	0.19
p		0.53	0.04	0.01	0.04	0.66

4 结论

1

.

ePTFE 30-40 [7]

AVG

[3]

AVG 2 7 3

5 [8] AVG

2 AVG 24-72 3 16 9

14 62

26

3 B

AVG

2-3

12-16

AVG

[9]

24

AVG

参考文献：

[1]
: (2)[J].
, 2019,18(6):365-381.
[2] , , , .29 ACUSEAL
[J]. ,2018,17(2):99-101.
[3] , , , , .
[J]. ,2019,18(10):701-704.
[4] , , , , .
[J]. ,2015,15:122-124.
[5] .
[J]. , 2019,25(3):11-14.
[6] . TDP
[J]. , 2018,11(2):123-124.
[7] , .65
[J]. , 2015,7(4):259-260.
[8] , , . [J].
,2014,29(1):103.
[9] , , , , .
[J]. ,2014, z13(7):
684-685.

2016SHD010